Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Rare Hepatic Diseases, Crigler-Najjar Syndrome & Precision Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UGT1A1 drug discovery and metabolic safety validation.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Recombinant Protein (Wild-Type & Mutants) | UGT1A1 full-length & polymorphic variants (G71R, P364L, *28 promoter). High purity (>95%), Endotoxin <1EU/µg. Sequence verified by mass spec. | View UGT1A1 Products |
| Gene Delivery | UGT1A1 Promise-ORF / Lentivirus pre-made particles. Full-length ORF for stable hepatic cell line construction (Crigler-Najjar models). | View UGT1A1 Products |
| Benchmark Antibody | Anti-UGT1A1 recombinant monoclonal. Sequence-verified, suitable for Western blot, IHC & IF. | View UGT1A1 Products |
| Knockdown Validator | UGT1A1 siRNA set (three unique sequences). Specificity verification in glucuronidation assays. | View UGT1A1 Products |
| Related Target: UGT1A4 | UDP-glucuronosyltransferase 1A4. Compensatory pathway enzyme; cross-reactivity screening essential for drug development. | View UGT1A4 Products |
| Related Target: UGT1A9 | Primary hepatic & renal phase II clearance co-enzyme; essential for counter-screening overlapping xenobiotic substrates. | View UGT1A9 Products |
| Related Target: UGT2B7 | Major isoform for glucuronidation of carboxylic acids and opioids; critical for comprehensive ADME-Tox profiling. | View UGT2B7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphism-Driven Toxicity Evaluation (e.g., UGT1A1*28, G71R) | Purified recombinant mutant proteins with strict sequence verification (mass spec confirmed). |
| Enzymatic Activity Consistency & Native Glycosylation | HEK293-expressed with native glycosylation pattern; endotoxin controlled (<1EU/µg). |
| Stable Hepatocyte Model Generation | High-titer lentivirus particles for stable integration in HepG2, Huh7, and primary hepatocytes. |
| Cross-Species Preclinical Toxicology (Cyno/Mouse/Human) | Human, mouse, and cynomolgus ortholog proteins available with >95% purity & verified sequences. |
| Subfamily Selectivity Screening | Homolog panel (UGT1A4, UGT1A9, UGT2B7) rigorously verified by mass spectrometry for precision selectivity screening. |
Live UGT1A1 R&D Tracker
Market data and clinical milestones change daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (General)
- ➤ Crigler-Najjar Gene Therapy Trials
- ➤ Irinotecan Pharmacogenomics Studies
- ➤ Latest Resistance & Gene Therapy Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The research landscape surrounding UGT1A1 bifurcates into two main strategic arenas: rare hepatic disease gene therapy and precision oncology ADME-Tox safety profiling. In the therapeutic domain, UGT1A1 serves as the primary target for functional cure strategies addressing Crigler-Najjar Syndrome (Types I & II) and severe Gilbert’s syndrome phenotypes. Major biopharmaceutical players – including Genethon, AskBio, Selecta Biosciences, and Ultragenyx (UX111, AAV8-UGT1A1) – are advancing recombinant AAV vector gene therapies and LNP-mRNA enzyme replacement approaches to restore bilirubin glucuronidation. Concurrently, in oncology and systemic drug discovery, UGT1A1 remains indispensable for pharmacokinetic/drug-drug interaction (PK/DDI) assessments. The rise of antibody-drug conjugates (ADCs) using topoisomerase I inhibitor payloads (e.g., SN-38, exatecan derivatives) makes accurate characterization of UGT1A1-mediated clearance and patient-specific polymorphic vulnerabilities paramount to preventing dose-limiting hematological and gastrointestinal toxicities. The next wave of R&D demands hyper-accurate in vitro assay models that mimic clinical hepatic metabolism and genetic polymorphism variability. Furthermore, small-molecule chaperones (e.g., targeting G71R folds) and expanded pharmacogenomic companion diagnostics (UGT1A1*28, *6) for irinotecan therapy are reinforcing the need for validated high-purity reagents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy | Genethon, AskBio, Selecta Biosciences, Ultragenyx, Novartis | Crigler-Najjar Syndrome Type I / II | Expression & localization validation; need high-purity positive control antibodies and Promise-ORF lentivirus for pre-screening cellular uptake. |
| mRNA Therapeutics | Moderna, Ultragenyx, Arcturus Therapeutics | Metabolic liver diseases, hyperbilirubinemia | Enzyme replacement evaluation; need sequence-verified recombinant proteins as quantitative standards. |
| ADC & Small Molecule ADME-Tox | AstraZeneca, Daiichi Sankyo, Pfizer | Solid tumors (payload clearance profiling) | Polymorphism DDI screening; need mutant and wild-type enzymes and lentivirus-derived cellular models. |
| Small Molecule Chaperones | Mitsubishi Tanabe, Orphagen | Gilbert’s Syndrome | Protein folding/stability assays; need mutant G71R/Y486D proteins. |
| Pharmacogenomic Diagnostics | Roche, Myriad Genetics, Thermo Fisher | Irinotecan toxicity (colorectal cancer) | Genotype-phenotype correlation; need variant protein panels for assay development. |